Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.
Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.
In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.
With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.
Lantern Pharma Inc. (NASDAQ:LTRN) will feature in an interview on The RedChip Money Report on Bloomberg TV on August 20 at 7 p.m. ET. CEO Panna Sharma will discuss the company's RADR® platform, which uses AI to optimize oncology drug development, aiming to reduce costs and enhance efficiency. Lantern is developing four drug candidates across nine tumor targets, including two in phase 2 trials. The interview is expected to highlight strategic collaborations with esteemed institutions like Johns Hopkins and Fox Chase Cancer Center.
Lantern Pharma (NASDAQ: LTRN) has launched the Phase 2 clinical trial, Harmonic™, for LP-300 targeting never smokers with advanced NSCLC, beginning patient enrollment in Q3 2022. The company plans to submit IND applications for LP-184 and LP-284 in early 2023, with two Phase 1 trials for LP-184 and one for LP-284 expected to commence thereafter. Lantern reported cash holdings of $62.2 million as of June 30, 2022, despite a net loss of approximately $4.5 million for the quarter. The RADR® platform surpassed 21 billion data points, enhancing its capabilities for future partnerships.
Lantern Pharma (NASDAQ: LTRN) will host a webcast on August 8, 2022, at 4:30 PM ET to discuss its Q2 financial results and future milestones. The company, focused on oncology drug discovery using its proprietary RADR® AI platform, is developing four drug candidates and an ADC program. Lantern aims to identify patients likely to respond to its therapies. Panna Sharma, CEO, will lead the discussion. A replay will be available on their investor relations website.
Lantern Pharma (NASDAQ: LTRN) has received FDA clearance to initiate the Harmonic™ trial, a Phase 2 clinical study for LP-300 in never smokers with advanced non-small cell lung cancer (NSCLC). The trial will enroll 90 patients and evaluate the drug in combination with chemotherapy, building on previous successes where LP-300 demonstrated a 91% overall survival and a 125% two-year survival for this demographic. Enrollment is expected to start in Q3 2022, targeting an estimated market of $1.5 to $2 billion for NSCLC.
Lantern Pharma (NASDAQ: LTRN) announced a virtual key opinion leader (KOL) webinar on May 26, 2022, at 12:00 p.m. ET. The webinar will focus on glioblastoma multiforme (GBM) and the potential of their drug candidate LP-184 for treating GBM and other brain cancers. Experts Dr. John Laterra and Dr. Matthias Holdhoff from Johns Hopkins will lead discussions alongside Lantern's Chief Scientific Officer, Dr. Kishor Bhatia. The event coincides with Brain Tumor Awareness Month, highlighting the urgent need for effective treatments for brain cancers.
Lantern Pharma Inc. (NASDAQ: LTRN) announced its participation in five upcoming investor and scientific conferences in
Lantern Pharma (NASDAQ: LTRN) reported Q1 2022 financial results, revealing $65.2 million in cash and equivalents. The company utilizes its RADR® A.I. platform, which surpassed 20 billion data points, enhancing drug discovery capabilities. The HARMONIC™ Phase 2 trial for LP-300 is expected to enroll patients in Summer 2022. Lantern plans to submit an IND for LP-184 by Q3 2022, targeting solid tumors. R&D expenses increased to $2.7 million from $1.3 million year-over-year. A net loss of $4.1 million was recorded, up from $2.5 million in Q1 2021.
Lantern Pharma (NASDAQ: LTRN) announced Dr. Maria L. Maccecchini as a nominee for its Board of Directors during the Annual Meeting on June 8, 2022. Dr. Maccecchini, a seasoned biopharmaceutical executive, brings decades of experience, particularly in neurodegenerative diseases. Concurrently, Leslie W. Kreis, Jr. will not seek reelection. Lantern's President, Panna Sharma, emphasized Dr. Maccecchini's potential contributions to ongoing clinical trials. Lantern is focused on utilizing its RADR® platform to enhance oncology drug development.
Lantern Pharma (NASDAQ: LTRN) plans to release its Q1 2022 financial results on May 3, 2022, after market closure. Management will host a conference call at 4:30 PM ET to discuss these results and outline future milestones. Lantern Pharma utilizes its RADR® A.I. platform in oncology drug development, focusing on genomically-targeted therapeutics. Currently, the company is developing four drug candidates and an ADC program spanning nine tumor targets, with a commitment to optimize patient outcomes.
Lantern Pharma (NASDAQ:LTRN) will be featured on The RedChip Money Report on Bloomberg TV on April 16 at 7 p.m. ET. This program, which reaches approximately 73 million U.S. households, focuses on small-cap investing and includes interviews with company executives and Wall Street analysts. Lantern Pharma utilizes its RADR® AI platform for oncology drug discovery, with a pipeline of four drug candidates and an ADC program targeting eight tumor types, including two in phase 2 trials.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
What does Lantern Pharma Inc. specialize in?
What is the RADR platform?
How does Lantern Pharma's approach reduce drug development costs?
What is the company's strategy for growth?
How does Lantern Pharma use AI in drug development?
Who are the key collaborators with Lantern Pharma?
What are some of Lantern Pharma's recent achievements?
Why is precision medicine important in cancer treatment?
How does Lantern Pharma's strategy benefit cancer patients?